GlassScriptPhysician profile
Amanda L Chissell
NPI 1871033340
$5,767.01
in general payments reported to CMS, 2019-2025
23 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,123 · 2022: $1,452 · 2023: $1,426 · 2024: $1,221 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158 · Education: $33.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,158.08 |
| Education | $33.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,219.64 | 2021-2024 | |
| Ucb, INC. | $872.04 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $625.78 | 2021-2025 | Enbrel, Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $485.73 | 2021-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $261.61 | 2021-2024 | Tremfya, Stelara, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $213.28 | 2021-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $166.79 | 2022-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $155.27 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $119.72 | 2023-2025 | Idacio, Tyenne |
| Horizon Therapeutics Plc | $106.32 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $86.44 | 2021-2024 | Orencia |
| Sobi, INC | $84.48 | 2022-2024 | |
| Lilly USA, LLC | $57.05 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $56.59 | 2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $45.12 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $43.33 | 2024 | Hyrimoz |
| Pfizer INC. | $42.07 | 2021-2022 | |
| Genzyme Corporation | $33.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $17.52 | 2023 | Zilretta |
| Radius Health, INC. | $15.19 | 2025 | Tymlos |
| Currax Pharmaceuticals LLC | $14.53 | 2022 | |
| Bioventus LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Chissell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.